Condition: Lung Cancer · EGFR Gene Mutation · Sponsor: Dana-Farber Cancer Institute
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
This description comes directly from the study's public registry record.
Fernando Pacheco · 857-215-2794 · fernando_pacheco@dfci.harvard.edu
Kylee Coonradt · 617-582-8846 · kylee_coonradt@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute at Steward St. Elizabeth's | Brighton, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber Cancer Instiute Merrimack Valley | Methuen, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute South Shore | South Weymouth, Massachusetts, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06716580